Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using AI to discover new drugs. | Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine ...

ACD/Labs brings deep expertise in supporting analytical and process chemistry within pharmaceutical and chemical R&D workflows. Its industry-leading tools help scientists identify and characterize ...

AI-related healthcare is one of the spaces that have seen a significant rise in funding globally, Crunchbase data shows.

Choose Birmingham Business Journal as a preferred news source to see more of our reporting on Google.

Market opportunities lie in modernizing software development and validation approaches, emphasizing agility and continuous validation to meet changing needs, while ensuring compliance with FDA ...

Explore how Leen Kawas redefines support ecosystems for biotech entrepreneurs beyond traditional funding methods.

BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics (NASDAQ:ENTO) has just made one of the boldest moves in its history, a reinvention that trades long biotech timelines for imme ...

Life sciences giant Thermo Fisher Scientific has agreed to acquire clinical trials software company Clario for a consideration of up to $9.4bn.

Thermo Fisher Scientific has agreed to acquire Clario Holdings for up to $9.4 billion in cash and future-earnout payments.

Life sciences group Thermo Fisher has sealed an all-cash takeover of drug trial software maker Clario in a deal that values the technology group at up to $9.4bn.